VC dollars flowing into Europe

Is Europe suddenly drawing major biotech venture capital? Xconomy's Luke Timmerman argues as much. The latest example: Domain Associates, a Princeton, NJ- and San Diego-based venture firm has inked a deal with Russia's government-owned RusNano to invest as much as $760 million in Russia- and U.S.-based biotechs. While Russia is oriented in equal economic and geographical measure toward Asia, it also clearly has an eye toward Europe (and the U.S.) for expansion. Timmerman notes that Sofinnova Ventures and Versant Ventures are opening offices in Ireland and Switzerland, respectively, and will seek European investment opportunities. Story | Star-Ledger coverage

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.